Last reviewed · How we verify
Polyuria — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ddavp | DESMOPRESSIN | Ferring Pharms Inc | Factor VIII Activator | Vasopressin V1b receptor | 1978-01-01 | |
| Minirin | Minirin | Hormozgan University of Medical Sciences | Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Ferring Pharms Inc · 1 drug in Polyuria
- Hormozgan University of Medical Sciences · 1 drug in Polyuria
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Polyuria:
- Polyuria treatment updates — RSS
- Polyuria treatment updates — Atom
- Polyuria treatment updates — JSON
Cite this brief
Drug Landscape (2026). Polyuria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/polyuria. Accessed 2026-06-10.
Related
- Polyuria full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing